Literature DB >> 22285019

Molecular cytogenetic characterization of epithelioid hemangioendothelioma.

Cornelius Woelfel1, Thomas Liehr, Anja Weise, Jan Langrehr, Waleed Amin Kotb, Manuela Pacyna-Gengelbach, Detlef Katenkamp, Iver Petersen.   

Abstract

Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor whose pathological diagnosis can be difficult. In the literature two cases of EHE were found to harbor a balanced t(1;3)(p36.3;q25) translocation, suggesting a characteristic chromosomal rearrangement as cause for the development of EHE. In this study, 14 cases of EHE were investigated by interphase fluorescence in situ hybridization (FISH) directed against the translocation breakpoint 1p36.3. A subset of cases was also analyzed by comparative genomic hybridization (CGH) and image cytometry. Five out of eight cases that could be successfully analyzed by FISH harbored a chromosomal break in the 1p36.3 region. The break-apart signals were present in diploid nuclei, and less frequently also in tetraploid nuclei. In the latter, the chromosomal break was present twice, suggesting that polyploidy occurred after the chromosomal alteration. DNA cytometry confirmed that tetraploid cells were present in most examined cases with one case indicating almost equal amounts of diploid and tetraploid tumor cells. CGH revealed single chromosomal imbalances of unclear significance. We could confirm that EHE may harbor a recurrent mutation involving the 1p36.3 chromosomal region thus supporting the notion that the t(1;3)(p36.3;q25) translocation is a relevant genetic finding in this tumor entity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22285019     DOI: 10.1016/j.cancergen.2011.11.007

Source DB:  PubMed          Journal:  Cancer Genet


  9 in total

Review 1.  Combination capecitabine and bevacizumab in the treatment of metastatic hepatic epithelioid hemangioendothelioma.

Authors:  Augustine Lau; Steve Malangone; Myke Green; Ambuga Badari; Kathryn Clarke; Emad Elquza
Journal:  Ther Adv Med Oncol       Date:  2015-07       Impact factor: 8.168

Review 2.  Diagnostic and therapeutic challenges in hepatic epithelioid hemangioendothelioma.

Authors:  Akshitkumar M Mistry; D Lee Gorden; Jacob F Busler; Alice C Coogan; Beau S Kelly
Journal:  J Gastrointest Cancer       Date:  2012-12

3.  Epithelioid hemangioendothelioma of the liver as a rare indication for liver transplantation.

Authors:  Piotr Remiszewski; Ewa Szczerba; Piotr Kalinowski; Beata Gierej; Krzysztof Dudek; Mariusz Grodzicki; Marcin Kotulski; Rafał Paluszkiewicz; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 4.  [The new WHO classification and recent results in soft tissue tumor pathology].

Authors:  I Petersen
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

5.  Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma.

Authors:  Olivia Bally; Louis Tassy; Bertrand Richioud; Anne-Valérie Decouvelaere; Jean-Yves Blay; Olfa Derbel
Journal:  Clin Sarcoma Res       Date:  2015-04-23

6.  Intraosseous epithelioid haemangioendothelioma of the mandible: A case report and literature review.

Authors:  Haili Yang; Jun Wang; Li Song; Haixiao Zou
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

7.  Primary malignant epithelioid hemangioendothelioma of the pleura: A review and report of a novel case.

Authors:  Alireza Rezvani; Reza Shahriarirad; Amirhossein Erfani; Keivan Ranjbar
Journal:  Clin Case Rep       Date:  2022-08-11

8.  Hepatic epithelioid hemangioendothelioma and the danger of misdiagnosis: report of a case.

Authors:  Kyriakos Neofytou; Andreas Chrysochos; Nikolas Charalambous; Menelaos Dietis; Christos Petridis; Charalampos Andreou; Athanasios Petrou
Journal:  Case Rep Oncol Med       Date:  2013-02-28

9.  Pleural epitheliod hemangioendothelioma: What started as a liver fluke and ended up being almost mistaken for malignant mesothelioma.

Authors:  Omer H Jamy; Bryan Huber; Smith Giri
Journal:  Ann Thorac Med       Date:  2015 Oct-Dec       Impact factor: 2.219

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.